Monoclonal antibody specifically recognizing an epitope for switching to Th17 cell
AssigneeNational Cancer Center
InventorByoung Se Kwon
Life of this patent
Estimating the term…
Loading patent…
AssigneeNational Cancer Center
InventorByoung Se Kwon
Estimating the term…
The present invention relates to a novel epitope to convert T cell to type 17 helper T (TH17) cell. Specifically, the present invention relates to an epitope constituting the 41st to 50th amino acids (SEQ ID No. 2) of extracellular domain (ECD) of activation-inducible tumor necrosis factor receptor (AITR), an antibody recognizing the epitope, a polynucleotide encoding the epitope, a polynucleotide encoding the antibody, an expression vector comprising the polynucleotide encoding the epitope or antibody, a transformant introduced with the vector, a composition comprising the antibody for converting T cell to TH17 cell and a method of conversion for the same, a pharmaceutical composition comprising the antibody for preventing or treating infectious disease, a method for treating infectious disease using the antibody, a composition comprising the antibody for enhancing immunity, and a method, for enhancing immunity using the antibody.
A monoclonal antibody specifically recognizing an epitope of activation-inducible tumor necrosis factor receptor (AITR), wherein the epitope is represented by SEQ ID No. 2.
Dependencies are inferred from the claim text.